BOVINE LEUKEMIA VIRUS AS AN INDUCER OF BOVINE LEUKEMIA NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


BOVINE LEUKEMIA VIRUS AS AN INDUCER OF BOVINE LEUKEMIA

Animal Models of Retrovirus Infection and Their Relationship to AIDS. Salzman LA, ed. Orlando, Florida, Academic Press, p. 107-19, 1986.. Unique Identifier : AIDSLINE ICDB/87629269
Burny A; Bruck C; Cleuter Y; Couez D; Gregoire D; Kettmann R; Mammerickx M; Marbaix G; Portetelle D; Willems L; Dept. of Molecular Biology, Univ. of Brussels, Belgium


Abstract: This chapter on bovine leukemia virus as an inducer of bovine leukemia is divided into four parts: one quarter deals with molecular biology, tumor induction, and host-virus relationships; one quarter deals with immune responses; and the remainder deals with the relatedness of human T cell lymphotropic virus (HTLV) and bovine leukemia virus (BLV), with characteristics of the various HTLV isolates, with a possible model for AIDS induced by BLV in rabbits, and with transmission and host range. Leukemia induction in cattle by BLV is in many ways comparable to disease caused by HTLV. The systems are quite interchangeable, although the cell target is a B lymphocyte in the case of BLV and a T lymphocyte in the case of HTLV. BLV can also infect sheep, and goats can be experimentally infected with BLV. In a search for viral RNA expression in cultured bovine and sheep tumor cells, it was found that the bovine cells expressed very little viral RNA and that the sheep cells did not show any viral expression. These data further support earlier findings that BLV virus is necessary to initiate transformation but then is dispensable once a critical event has occurred. The order of genes in BLV provirus is gag, pol, env, followed by a region originally called leuk and now called lor. There is an open reading frame that expands over 924 nucleotides with a strongly conserved region in the 5' end. All animals infected with BLV react with very strong immunological responses against invading virus. Eight antigenic sites (A to H) have been distinguished on gp51, the major envelope glycoprotein; infected cattle develop antibodies against F, G, and H. The possibility of mimicking an AIDS reaction in experimental animals with BLV seems very strong. The ruminants and other animals that naturally develop tumors from BLV do not show immunodeficiency syndrome. However, experimental infections of chimpanzees, macaques, pigs, and rabbits are successful. Ticks, insect vectors, and the like do not seem to contribute to transmission in temperate climates, but their role in tropical conditions is unknown.
Keywords: Animal Antibodies, Viral/BIOSYNTHESIS Antigenic Determinants Base Composition Cattle Comparative Study Female Genes, Viral Glycoproteins/METABOLISM Human HTLV-BLV Viruses/IMMUNOLOGY/METABOLISM Leukemia/IMMUNOLOGY/MICROBIOLOGY/TRANSMISSION/*VETERINARY Leukemia Virus, Bovine/IMMUNOLOGY/METABOLISM/*PATHOGENICITY Male Nucleic Acid Hybridization Rabbits RNA, Messenger/GENETICS RNA, Viral/GENETICS Viral Envelope Proteins/METABOLISM MONOGRAPH

KWDanimalantibodies,viral/biosynthesisantigenicdeterminantsbasecompositioncattlecomparativestudyfemalegenes,viralglycoproteins/metabolismhumanhtlv-blvviruses/immunology/metabolismleukemia/immunology/microbiology/transmission/KWDveterinaryleukemiavirus,bovine/immunology/metabolism/KWDpathogenicitymalenucleicacidhybridizationrabbitsrna,messenger/geneticsrna,viral/geneticsviralenvelopeproteins/metabolismmonograph
870430
M8740289


Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .